Position in WHWK
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$79,291
+$41,288 QoQ
Shares Held
22,983
+46.4% QoQ
Ownership
0.046%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2022
10 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in WHWK Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026XTX Topco Ltd holds $287,762,779 across 374 Biotechnology names. WHWK ranks #280 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ROIV |
Roivant Sciences Ltd.
|
255,431 | $7,075,438 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
15,632 | $6,980,313 | |
| 3 | IONS |
Ionis Pharmaceuticals Inc
|
80,519 | $6,046,171 | |
| 4 | EXEL |
Exelixis, Inc.
|
134,413 | $5,764,973 | |
| 5 | NUVL |
Nuvalent, Inc.
|
53,354 | $5,466,117 | |
| 6 | AGIO |
Agios Pharmaceuticals, Inc.
|
160,880 | $5,442,570 | |
| 7 | BMRN |
Biomarin Pharmaceutical Inc
|
93,609 | $5,287,972 | |
| 8 | RYTM |
Rhythm Pharmaceuticals, Inc.
|
59,502 | $5,174,888 |
All Filings in WHWK
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $79,291 | 22,983 | Shares | Defined | 2026-05-15 | |
| 2025-12-31 | $38,003 | 15,704 | Shares | Defined | 2026-02-17 | |
| 2025-09-30 | $37,582 | 19,780 | Shares | Defined | 2025-11-14 | |
| 2024-12-31 | $41,787 | 13,245 | Shares | Defined | 2025-02-13 | |
| 2024-09-30 | $32,117 | 15,591 | Shares | Defined | 2024-11-14 | |
| 2024-03-31 | $62,010 | 26,500 | Shares | Defined | 2024-05-13 | |
| 2023-12-31 | $20,662 | 10,229 | Shares | Defined | 2024-02-13 | |
| 2023-03-31 | $87,444 | 12,078 | Shares | Defined | 2023-05-12 | |
| 2022-12-31 | $182,558 | 14,229 | Shares | Defined | 2023-02-14 | |
| 2022-09-30 | $145,623 | 10,306 | Shares | Defined | 2022-11-14 | |
| No filing history on record for this holder in this stock. | ||||||